ReviewDrug delivery and translational research2026
Stimuli-responsive nanocarriers for targeted mRNA therapeutics: a paradigm shift in mRNA delivery for biomedical applications.
Review in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Delivery of mRNA Therapeutics Beyond Infectious Diseases: Design Innovations and Applications in Oncology, Cardiovascular, and Rare Genetic Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines · 2026Review
- Smart microdevices for biomedical drug delivery: endogenous stimuli as the key to safer therapeutics.RSC advances · 2026Review
- Engineering Nanocarriers for Dopamine Stabilization and Targeted Brain Delivery: Mechanisms, Approaches and Translational Challenges.International journal of nanomedicine · 2026Review
- Stimuli-Responsive Cell-Mimetic Vesicles for Advanced Pharmaceutical Systems.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Messenger RNA (mRNA) based therapeutics have emerged as a transformative modality with immense potential for treating infectious diseases, cancer, genetic disorders, and other complex conditions. Despite their promise, clinical translation has been challenged by mRNA's intrinsic instability, rapid degradation, and limited target specificity. The therapeutic value of mRNA lies in its ability to precisely modulate or restore protein expression, offering a versatile platform for personalized medicine. While conventional delivery approaches have yielded modest improvements, the integration of nanotechnology, particularly stimuli-responsive, nanoparticle-mediated systems, represents a breakthrough in overcoming these limitations. These advanced nanocarriers respond to both endogenous physiological triggers (such as pH shifts, redox gradients, reactive oxygen species, enzymatic activity, and hypoxic environments) and exogenous stimuli (including light, ultrasound, magnetic fields, and temperature changes), thereby enabling controlled, site-specific, and temporally regulated mRNA release. This dual responsiveness enhances therapeutic efficacy by improving mRNA stability, bioavailability, and minimizing off-target immune activation. This review highlights the design principles, mechanisms, and therapeutic applications of stimuli-responsive nanocarriers in mRNA delivery. It underscores recent innovations in nanoparticle engineering that address existing challenges and pave the way for next-generation precision medicine. Together, these advancements signal a paradigm shift in targeted mRNA therapy, offering new hope for treating previously intractable diseases.
Indexed as
Identifiers
41593245What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.